Key result
NOACs were noninferior to standard-intensity warfarin in preventing VTE recurrence, with edoxaban ranking first (HR 0.99; 95% CrI 0.70-1.39), and apixaban ranking first for bleeding control.
Why the study?
Many anticoagulant strategies are available for extended treatment of venous thromboembolism, but little guidance exists on which drug is most effective and safe.
Do NOACs prevent VTE recurrence and reduce bleeding compared to standard-intensity warfarin in adults requiring extended treatment for VTE?
Population
Adults with VTE across 13 eligible RCTs
Comparison
NOACs vs other anticoagulants or placebo
Design
Network meta-analysis of randomized controlled trials
Authors
Loading...
Supports NOAC selection over warfarin for VTE; reinforces evidence base with agent-specific rankings.
Meta-Analysis
Do NOACs prevent VTE recurrence and reduce bleeding compared to standard-intensity warfarin in adults requiring extended treatment for VTE?
Hazard Ratio: 0.99 (95% CI 0.7–1.39)
In the extended treatment of VTE, NOACs offer similar efficacy to standard-intensity warfarin but with a significantly lower risk of bleeding, with apixaban demonstrating the best safety profile.
Liu et al. (2022) conducted a meta-analysis in Venous thromboembolism. Novel oral anticoagulants (NOACs) vs. Standard-intensity warfarin was evaluated on VTE recurrence (HR 0.99, 95% CI 0.70-1.39). NOACs were noninferior to standard-intensity warfarin in preventing VTE recurrence, with edoxaban ranking first (HR 0.99; 95% CrI 0.70-1.39), and apixaban ranking first for bleeding control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: